Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
| Image |  |
|---|---|
| Description | article by Martin R Gaudinski et al published 2 March 2019 in The Lancet |
| Author/s |
author: John Misasi Martin R Gaudinski Nancy Sullivan Carolyn Laurencot Edmund Capparelli Barney S. Graham Kevin Carlton Emily Coates Richard A Koup Martha Nason Adrian B. McDermott Sandra Sitar Nina M. Berkowitz John R. Mascola Ingelise J Gordon Alicia T. Widge Galina V Yamshchikov Laura Novik Julie Ledgerwood LaSonji A. Holman Katherine V Houser Cristina A Carter Charla A Andrews |
| Publication date | March 2, 2019 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |